$EXASGreen: Entry Point
Blue: Start of Week
Red: End of Week
Thumbs Up: Trade Available for Week
Numbers: Price Targets
*For share traders only. Not meant for options.
EXAS trade ideas
EXAS a Bullish OutlookAs I predicted before, I had a 100% success rate. Let's consider a long position based on the current technical indicators.
Trend Line: We have a yellow trend line where the price bounced in 2016 and 2022. We are now approaching this trend line again.
Bat Pattern: The bat pattern indicates that point C, which is the 0.886 Fibonacci retracement, aligns exactly with the yellow trend line. The price at point C is $37.87.
Parallel Channel: The parallel channel also converges at the same point.
Given these confluences, the price is expected to bounce from this level. Here is my trading plan:
Stop Loss: $29.00
Entry Level: $37 / $38
First Take Profit: $99.00 (50% of the position)
Final Take Profit: $140.00
Additionally, the RSI has reached the oversold area, further supporting the likelihood of a price bounce from this level.
Disclaimer: I am not a financial advisor.
Exact Sciences: Anticipating a Market Correction Amidst OverbougExact Sciences is exhibiting bullish tendencies at present, but it's critical to anticipate a substantial correction upon touching, or descending below, the 0.618 Fibonacci retracement level. The stock is likely to retreat to around $70, a significant support level we've observed. The patterns in play – the AB=CD pattern and a yet unconfirmed bearish bat pattern – suggest this potential correction.
Moreover, the stock's weekly Relative Strength Index (RSI) indicates an overbought situation, signaling a possible reversal in the near future. While I'm an advocate for Exact Sciences, particularly their efforts in cancer diagnostics and treatment, it's important to ground our expectations in reality. In the long run, the company represents a viable investment opportunity, but the current overbought status implies that a better entry point may be forthcoming.
Never be swayed by the fear of missing out; remember, purchasing at a lower price could yield up to a 50% gain compared to the current pricing. Starting at $87, I intend to short the stock, continuing to do so until we see the anticipated market correction. Despite the current optimism, it's improbable for the stock to soar indefinitely.
While Exact Sciences' research in cancer treatment shows promise, it's essential to remember that we are yet to find a definitive cure for cancer. Factors such as diet and environmental pollution play a crucial role in the incidence of the disease. Despite these realities, I plan to buy shares to support the company's mission, but not at the inflated current price.
Based on my technical analysis, it seems likely we are due for a correction, possibly down to the $70 level.
IPlease note that while I follow the markets closely and share my insights, I am not a licensed financial advisor. It's always crucial to do your own research or consult with a financial advisor before making investment decisions.
Exact Sciences (EXAS) - Continuation of the DowntrendBased on my previous technical analysis where Exact Sciences exhibited bullish tendencies but warned of a possible substantial correction around the $70 level, we now find ourselves at a critical junction. Two possible scenarios could unfold from here: a bearish three drives pattern leading to a bounce back to around $123 or a continuation of the downtrend following the break of a rising wedge pattern.
Scenario 1: Bearish Three Drives Pattern
If EXAS bounces back to around $123, it may complete a bearish three drives pattern. This pattern generally suggests a reversal is imminent. I intend to start shorting the stock around $120-$124 levels, anticipating a drop to ~$61.
Scenario 2: Rising Wedge Break
On the other hand, EXAS has broken the trend line of a previously noted rising wedge, signaling a potential continuation of the bearish outlook. The target for this bearish breakout lies between $48 and $61.
Key Support Levels to Watch:
$79: If broken, it's likely we'll head to $61.
$60: If this level fails to hold, expect a plunge towards the $50 zone.
In this scenario, my plan would be to go long around the $53-$57 levels.
Risk Management:
In both scenarios, it's crucial to set stop-loss orders and take other risk management measures to protect your portfolio
Conclusion:
While I maintain a favorable view of Exact Sciences for their work in cancer diagnostics and treatment, the technicals suggest caution is warranted at these levels.
Disclaimer: I am not a licensed financial advisor. The information here is for educational purposes. Always conduct your own research and consult a financial advisor before making any investment decisions.
ABC Correction looks to be over for EXASCorrection could now be over @ 62% retrace.
Looking for a move up to the upper trend line into 2027 based on previous cycles.
+ Momentum divergence at the c wave low suggests energy is building for the next move higher.
Trendchanges and its author are not registered financial advisors. Everything that is documented by Trendchanges and its author within the news letter or online should be interpreted as market commentary and not as investment advise or instructions to buy or sell any financial asset.
Trading and investing carries risk and you should fully understand the risks involved.
Its recommended that you confer with an independent financial advisor who can assess the risks for your own financial situation. This is important as trading can result in the complete loss of your capital. If trading on margin losses can exceed your original deposit.
Trendchanges and its author will not accept any liability for any losses resulting from the use of the material presented if readers do decide to take action as a result of information communicated in the newsletter or online.
Although every effort is made to insure the accuracy of the information contained within this publication, Trendchanges and its author does not guarantee the accuracy of the information, either from the content within or from any external third part links which my be used.
Past trading performance is not an indication or guarantee of future results.
Exact Sciences Corporation Fundamentally The Company have a really good quarterly results and is looking cheap at this price. Technically we can see buying pressure from good area of support. Price might go as high as 84.50/85.50 $ before next quarterly results.
EXAS - Amazing symmetry
If you want to know where price is going to be, look for the history. Will this break out of this range and head higher or flush below?
if it can close above 65 this week, I would keep an eye on it above 68. It moves quickly so a news could push this over/under.
Long via commons and options. stop loss = 63.0
Exact sciences corp Exact Sciences is a biotech stock that is overpriced.
It's time to sell
We touched 3 times the resistance line of a rising wedge pattern, impulsive wave pattern, and RSI 71 weekly overbought zone, the Q2 doesn't seem good.
A leg down to 60$ retesting 69$ which is the resistance line of a rising wedge dropping below 40$ and based on the Q2 announcement either we drop hard to 25$ zone or we bounce back to 0.886 FIb 146$ zone which is a sign of a bearish bat pattern
please take note that I'm not a financial advisor
Long Trade in EXASExact Sciences is a biotech stock showing high relative strength.
Following a 50% jump in January, the stock is tightening with pullbacks getting shallower from left to right.
This is a sign of seller digestion which we often see before a new breakout to the upside.
EXAS is also finding support at key moving averages which appear to be holding up the stock.
I would consider buying on a breakout above $69.
$EXAS Setting UpI am not looking to take any more risk tomorrow but $EXAS is setting up an early turn low risk entry.
Exas Almost there, but has to be perfect in this marketEXAS is almost there. Trend is building up. May be little bit tightening and tighter pivot
Almost Meeting the Criteria. Almost!!Almost meet my criteria, just missing a parameter from Trend Template. 150 D > 200 D.. Tighting though. Would be on my watchlist
EXAS to 223 in 2023Going long for 2023. EXAS is looking bullish. Chart lines go WAY BACK! Let's see if price respects them.
Exact Sciences EXAS Operating Losses;.Another 70% to Fall!! The EXAC chart has been a downtrend from $130 to $40 with a High VOLUME. The stock is making new bottoms while insiders and the executive team have constantly been selling at any price! The stock is down 70% from its high of $137! How many insiders bought any shares at $40? NONE! BIG ZERO! The technical chart is obvious. On the fundamentals:
Revenue of company lost -$745Million on Revenue of $1.85 Billion! Cash incineration company highly leveraged!
Losing money fast is another indicator. The main product, Cologuard, is being advertised on TV for $680, cash $500. However, your doctor needs to order this! Most doctors, including my doctor, didn't want to use this versus colonoscopy because of liability and not a practical test with multiple false positives in case of blood and not detecting Polyps!
Cologuard is 92% accurate with 13% FALSE positive and 8% False Negative! The fit-tests that most doctors use to find blood in stool are $25-$49, then they recommend colonoscopy to see colon Polyps! This company bought tons of other companies at crazy valuations. The CEO is an attorney from Michigan state who comes to TV/CNBC on Cramer shows to pump and dump this stock to the public. (See youtube videos) The company has 3.5 billion in long-term and short-term liability with bad operating cash burns. The TV ads are the kiss of death to increase revenue at huge costs. Definition of stock that is 70% down then drops 2/3 to be 90% from its high.
Last Catherine Wood of ARK investment loves this stock owning 4.4% or $662million. I have seen Catie's garbage analysis on the stock with Tesla's $4600 target regardless of how many cars they sell! She is like Softbank putting her investment in shiny useless objects like Coinbase, upstart, and telehealth at crazy valuations.
Exact Science has NO SCIENCE or Exact.
EXAS will follow PACB $4, Pacific Bioscience to single-digit stock!
A crowded diagnostic market with many competitors, falling prices, and expensive doctors as customer acquisition will not work!
My 2 cents and do your homework, and I am not responsible for your trades.
Exact Science is Exactly what we look for. :)Nice bat forming at a historical Ice line form way back when. Divergences are forming on other oscillators but Class A reversal divergence is on the RSI
Exact Sciences (NASDAQ: $EXAS) Breakout Off 0.786 Fib! 🎯Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
Exas elliot wave Exas elliot wave, currently on a correction. Finished 5 wave and currently on a correction
EXASExact Sciences Corp. is a molecular diagnostics company specialising in the detection of early stage cancers. The company's initial focus was on the early detection and prevention of colorectal cancer, in 2014 it launched Cologuard, the first stool DNA test for colorectal cancer. Since then Exact Sciences has grown its product portfolio to encompass other screening and precision oncological tests for other types of cancer.
EXAS: Looks like a good growth company (Request: logicalBird1984Strong support at $90. However, down trend line also is strong. Weakening momentum as confirmed by the MACD indicator.
Likely to see the down trendline holding down prices. Will have to see which Demand Zone (green boxes) provides the support. If it doesn't and it breaks below the $90 support, then it might fall to $75-$80. Definitely don't want to see it fall below $70.
Now, if it breaks above the down trendline, then the next test will be the immediate Supply Zone (red box). If it is broken decisively, then the bulls are back in control. We can look to buy at the next retracement, likely around $100-105.
I won't buy at this point because I'm not exactly bullish right now. But please do your own due diligence.
Disclaimer: I'm not giving any trading and investing advice. I'm just sharing my chart observations.
If you have any symbols that you'd like me to analyze, feel free to drop me a comment.
this company's valuation is blasphemyEXAS just under doubled revenue from 2019 to 2020 and is trading at 2019 levels
HUH????
a biotech company with a positive EBITDA not crazy multiples and a testing kit that does not need FDA approval
it is clearly working look at revenue growth, and before you talk about the loss relax they have tons of cash
second biggest ARKG holding and a two-ish year bullflag
i think the breakout of this one will lead to a big bull to the high $100's and the low $200s
it'll take a while I'm not trading it I'm investing in it
also oscellator looks like it's at a bottom and at the 200 ema
Trading Idea - #ExactSciencesSELL
ENTRY: 96.50 USD
TARGET: 71.71 USD (26% profit)
STOP: 111.30
Exact Sciences Corporation is a cancer screening and diagnosis company. The company focuses on the early detection and prevention of several forms of cancer.
1.) The price broke within few days through 3 support areas! CAUTION!
2.) The profitability of business activity is a major weakness of the company.
3.) The ratio of "company value to sales" places the company among the world's most expensive companies. Oberbought?
4.) The only positive thing I can say here, is that the share price is starting a mini-consolidation around the 97.50 USD support zone. I am afraid that this will not last for long time...
Eros STX Global Corp 🧙Eros STX Global Corp is a film production and distribution company. It distributes its film content across multiplex chains and stand-alone theatres and broadcasts television content via tie-ups with channels such as ZEE TV and Star TV. The company also has a digital presence through its website; www.erosnow.com and an independent channel on Youtube. Geographically, it has a presence in India, North America, Europe and Rest of the world. The company primary revenue streams are derived from three channels: theatrical, television syndication and digital and ancillary.
If you want not to miss ideas like this one ,🎯 subscribe and press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!
$EXAS with a neutral outlook following its earnings #BeststocksThe PEAD projected a neutral outlook for $EXAS after a negative under reaction following its earnings release placing the stock in drift D
If you would like to see the Drift for another stock please message us. Also click on the Like Button if this was useful and follow us or join us.
